Prophylactic donor-derived CD19 CAR-T cell infusion for preventing relapse in high-risk B-ALL after allogeneic hematopoietic stem cell transplantation

Wenyi Lu^{1

2

3}, Hairong Lyu^{2

3}, Xia Xiao^{2

3}, Xue Bai^{2

3}, Meng Zhang^{2

3

4}, Jiaxi Wang^{2

3}, Yedi Pu^{2

3}, Juanxia Meng^{2

3}, Xiaomei Zhang^{2

3}, Haibo Zhu^{2

3}, Ting Yuan^{2

3}, Bing Wang^{2

3}, Xin Jin^{2

3}, Xinping Cao^{2

3}, Zhao Wang^{2

3}, Tianle Xie^{2

3}, Haotian Meng^{2

3}, Alexey V Stepanov⁵, Alexander G Gabibov⁵, Yuxin An^{2

3}, Rui Sun^{2

3}, Yu Zhang^{2

3}, Mikhail A Maschan⁶, Zunmin Zhu^#⁷, Hongkai Zhang^#⁸, Mingfeng Zhao^#^{9

10}

Affiliations

¹ Department of Hematology, Institute of Hematology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, Zhengzhou, China.
² Department of Hematology, Tianjin First Central Hospital, Tianjin, China.
³ Department of Hematology, Nankai University Affiliated First Central Hospital, Tianjin, China.
⁴ Department of Hematology, Beijing Children's Hospital, Beijing, China.
⁵ M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia.
⁶ Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
⁷ Department of Hematology, Institute of Hematology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, Zhengzhou, China. zhuzm1964@163.com.
⁸ State Key Laboratory of Medicinal Chemical Biology and College of Life Science, Nankai University, Tianjin, China. hongkai@nankai.edu.cn.
⁹ Department of Hematology, Tianjin First Central Hospital, Tianjin, China. mingfengzhao@sina.com.
¹⁰ Department of Hematology, Nankai University Affiliated First Central Hospital, Tianjin, China. mingfengzhao@sina.com.

^# Contributed equally.

PMID: 38632315
PMCID: PMC11147756
DOI: 10.1038/s41375-024-02251-5

Prophylactic donor-derived CD19 CAR-T cell infusion for preventing relapse in high-risk B-ALL after allogeneic hematopoietic stem cell transplantation

Wenyi Lu et al. Leukemia. 2024 Jun.

. 2024 Jun;38(6):1419-1422.

doi: 10.1038/s41375-024-02251-5. Epub 2024 Apr 17.

Authors

Affiliations

¹ Department of Hematology, Institute of Hematology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, Zhengzhou, China.
² Department of Hematology, Tianjin First Central Hospital, Tianjin, China.
³ Department of Hematology, Nankai University Affiliated First Central Hospital, Tianjin, China.
⁴ Department of Hematology, Beijing Children's Hospital, Beijing, China.
⁵ M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia.
⁶ Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
⁷ Department of Hematology, Institute of Hematology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, Zhengzhou, China. zhuzm1964@163.com.
⁸ State Key Laboratory of Medicinal Chemical Biology and College of Life Science, Nankai University, Tianjin, China. hongkai@nankai.edu.cn.
⁹ Department of Hematology, Tianjin First Central Hospital, Tianjin, China. mingfengzhao@sina.com.
¹⁰ Department of Hematology, Nankai University Affiliated First Central Hospital, Tianjin, China. mingfengzhao@sina.com.

^# Contributed equally.

PMID: 38632315
PMCID: PMC11147756
DOI: 10.1038/s41375-024-02251-5

No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

**Fig. 1. Clinical outcomes, CAR-T proliferation, and peripheral blood biomarkers after donor-derived CD19 CAR-T cell infusion.**
A Swimmer plot depicting clinical outcomes after CD19 CAR-T cell maintenance therapy. B The 2-year cumulative incidence of relapse after CD19 CAR-T cell infusion. C The probability of 2-year progression-free survival after CD19 CAR-T cell infusion. D Proliferation of CAR-T cells in patients who received a high dose (>2 × 10⁶/kg, n = 10) and those who received a low dose (≤2 × 10⁶/kg, n = 13) of CAR-T cells. E The peak level of serum IL-6 after CAR-T cell infusion in high dose group (n = 10) or low dose group (n = 13). F The peak level of serum CRP (c-reactive protein) after CAR-T cell infusion in high dose group (n = 10) or low dose group (n = 13). Data are represented as mean ± SEM.

See this image and copyright information in PMC

Cited by

Efficacy of blinatumomab as maintenance therapy for B-lineage acute lymphoblastic leukemia/lymphoma following allogeneic hematopoietic cell transplantation.
Huang J, Shi B, Yu S, Xue M, Wang L, Jiang J, Hu J, Zhu J, Chen S, Shen L, Cao W, Cao Y, Hu X. Huang J, et al. Blood Cancer J. 2024 Jul 8;14(1):109. doi: 10.1038/s41408-024-01092-w. Blood Cancer J. 2024. PMID: 38977689 Free PMC article. No abstract available.
Less frequent complications following CAR T-cell therapies: hemophagocytic lymphohistiocytosis, graft-versus-host disease, thrombotic microangiopathy, coagulation disorders and secondary malignancies: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee.
Ortí G, Dachy G, Graham CE, Peric Z, Alarcon A, Del Bufalo F, Doglio M, Henter JI, Roddie C, Stewart O, Van de Donk WCJ, Velasco R, Aljurf M, Ruggeri A, Onida F, Sánchez-Ortega I, Yakoub-Agha I, Penack O. Ortí G, et al. Bone Marrow Transplant. 2025 Jun;60(6):751-758. doi: 10.1038/s41409-025-02567-5. Epub 2025 Apr 9. Bone Marrow Transplant. 2025. PMID: 40205032 Review.
Recent advances in universal chimeric antigen receptor T cell therapy.
Jiang N, Yang Z, Miao H, Xing S, Wang S, Li N. Jiang N, et al. J Hematol Oncol. 2025 Aug 29;18(1):82. doi: 10.1186/s13045-025-01737-8. J Hematol Oncol. 2025. PMID: 40883768 Review.

References

1. Liu J, Zhong JF, Zhang X, Zhang C. Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies. J Hematol Oncol. 2017;10:35. doi: 10.1186/s13045-017-0405-3. - DOI - PMC - PubMed
1. Hua JS, Zhang J, Zhang XY, Wu XX, Zhou LL, Bao XB, et al. Donor-derived anti-CD19 CAR T cells compared with donor lymphocyte infusion for recurrent B-ALL after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2021;56:1056–64. doi: 10.1038/s41409-020-01140-6. - DOI - PubMed
1. Zhao XY, Xu ZL, Mo XD, Chen YH, Lv M, Cheng YF, et al. Preemptive donor-derived anti-CD19 CAR T-cell infusion showed a promising anti-leukemia effect against relapse in MRD-positive B-ALL after allogeneic hematopoietic stem cell transplantation. Leukemia. 2022;36:267–70. doi: 10.1038/s41375-021-01351-w. - DOI - PubMed
1. Si X, Gu T, Liu L, Huang Y, Han Y, Qian P, et al. Hematologic cytopenia post CAR T cell therapy: etiology, potential mechanisms and perspective. Cancer Lett. 2022;550:215920. doi: 10.1016/j.canlet.2022.215920. - DOI - PubMed
1. Jain T, Knezevic A, Pennisi M, Chen Y, Ruiz JD, Purdon TJ, et al. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 2020;4:3776–87. doi: 10.1182/bloodadvances.2020002509. - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Prophylactic donor-derived CD19 CAR-T cell infusion for preventing relapse in high-risk B-ALL after allogeneic hematopoietic stem cell transplantation

Affiliations

Prophylactic donor-derived CD19 CAR-T cell infusion for preventing relapse in high-risk B-ALL after allogeneic hematopoietic stem cell transplantation

Authors

Affiliations

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical